Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J.

Citius Pharmaceuticals, Inc. Reports Fiscal

Full Year 2024 Financial Results and Provides Business Update

Clinical and regulatory success in 2024 expected

to drive value in 2025

CRANFORD, N.J., December 27, 2024 -- Citius

Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to

the development and commercialization of first-in-class critical care products today reported business and financial results for the

fiscal full year ended September 30, 2024.

Fiscal Full Year 2024 Business Highlights and

Subsequent Developments

Financial Highlights

"In fiscal year 2024 we drove tremendous

progress in our pipeline. It was a transformative year, marked by our first FDA approval and significant clinical milestones. The approval

of LYMPHIR and the positive Phase 3 results for Mino-Lok underscore our commitment to developing innovative therapies. Our

team successfully responded to FDA comments related to the biologics license application for LYMPHIR and ultimately gained FDA approval.

Productive engagement with the FDA regarding the positive results of our Phase 3 Mino-Lok trial and Phase 2 Halo-Lido trial clarified

our next steps for both programs. We anticipate continued engagement with the agency in the coming year and look forward to their guidance.

Additionally, we are exploring strategic partnerships and licensing opportunities to maximize the potential of our portfolio and bring

these important therapies to market efficiently," stated Leonard Mazur, Chairman and CEO of Citius Pharma.

"Looking ahead, our priorities for fiscal

year 2025 include launching LYMPHIR through our majority-owned subsidiary, Citius Oncology, driving the clinical and regulatory

strategies for Mino-Lok and Halo-Lido, fortifying our financial position, and applying a disciplined approach to resource allocation.

We expect to launch LYMPHIR in the first half of 2025 and distribute CTOR shares to Citius Pharma shareholders by the end of the year,

pending favorable market conditions. Our goal remains to deliver value for patients, healthcare providers, and shareholders. With a clear

vision and a strong team, we are well-positioned to execute on our mission of bringing innovative therapies to market," added Mazur.

Year 2024 Financial Results:

As of September 30, 2024, the Company had $3.3

million in cash and cash equivalents.

As of September 30, 2024, the Company had 7,247,243

common shares outstanding, as adjusted for the 1-for-25 reverse stock split of the Company's common stock, effected on November

During the year ended September 30, 2024, the

Company received net proceeds of $13.8 million from the issuance of equity. The Company expects to raise additional capital to support operations.

Research and Development (R&D) Expenses

R&D expenses were $11.9 million for the full

year ended September 30, 2024, compared to $14.8 million for the full year ended September 30, 2023. The decrease in R&D expenses

primarily reflects the completion of the Halo-Lido trial and completion of activities related to the regulatory resubmission for LYMPHIR,

offset by shutdown costs associated with the end of the Phase 3 trial for Mino-Lok.

We expect research and development expenses to

decrease in fiscal year 2025 as we continue to focus on the commercialization of LYMPHIR through our majority-owned subsidiary, Citius

Oncology and because we have completed the Phase 3 trial for Mino-Lok.

General and Administrative (G&A) Expenses

G&A expenses were $18.2 million for the full

year ended September 30, 2024, compared to $15.3 million for the full year ended September 30, 2023. The increase was primarily due to

costs associated with pre-launch and market research activities associated with LYMPHIR. General and administrative expenses consist primarily

of compensation costs, professional fees for legal, regulatory, accounting and corporate development services, and investor relations

Stock-based Compensation Expense

For the full year ended September 30, 2024, stock-based

compensation expense was $11.8 million as compared to $6.6 million for the prior year. The increase of $5.2 million is largely due to

the grant of options under the Citius Oncology stock plan. Stock-based compensation expense under the Citius Oncology stock plan was $7.5

million during the year ended September 30, 2024, compared to $2.0 million for the year ended September 30, 2023, as the plan was initiated

in July 2023. For the years ended September 30, 2024 and 2023, stock-based compensation expense also includes $47,547 and $130,382, respectively,

for the NoveCite stock option plan. In fiscal years 2023 and 2024, we granted options to our new employees and additional options to other

employees, our directors, and consultants.

Net loss was $39.4 million, or ($5.97) per share

for the year ended September 30, 2024, compared to a net loss of $32.5 million, or ($5.57) per share for the year ended September 30,

2023, as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of $5.3 million offset

by a decrease of $1.6 million in other income. Operating expense increased due to increases in stock-based compensation and general and

administrative expenses, which were offset by decreased research and development expense.

About Citius Pharmaceuticals, Inc.

Citius Pharma is a biopharmaceutical company dedicated

to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR , a

targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also

includes Mino-Lok , an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and

CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for

Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged

with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.

Forward-Looking Statements

This press release may contain "forward-looking

statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these

statements by the fact that they use words such as "will," "anticipate," "estimate," "expect,"

"plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking

statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our

business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those

currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our ability to raise additional money to fund our

operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR through our majority-owned subisity

and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance

thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related

to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including

those from our existing and any new pipeline assets; our ability to maintain compliance with Nasdaq's continued listing standards;

our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and

maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage

of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters;

our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government

regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These

risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute

guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding

our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius

Pharma's Annual Report on Form 10-K for the year ended September 30, 2024, filed with the SEC on December 27, 2024, as updated by

our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any

obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any

change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required

-- Financial Tables Follow -

CITIUS PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS

SEPTEMBER 30, 2024 AND 2023

Reflects a 1-for-25 reverse stock split effective

CITIUS PHARMACEUTICALS, INC.